Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on…
Read More »Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on…
Read More »